- Moving Target: New Biology Casts TREM2 as a Shifty Mark
Series - AD PD™ 2025: Advances in Science Therapy: Part 1 of 15: Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s Part 2 of 15: New Partnership Forms to Harness AI for Alzheimer’s Research Part 3 of 15: Moving Target: New Biology Casts TREM2 as a Shifty Mark Part 4 of 15: TREM2: A Chill Pill for Neurons? Part 5 of 15: Trialists Grapple with How to Outsmart
- TREM2 | ALZFORUM
Triggering receptor expressed on myeloid cells 2 (TREM2) is a receptor of the innate immune system expressed on microglia, macrophages, dendritic cells, and osteoclasts TREM2 is a member of the immunoglobulin superfamily Endogenous ligands of this receptor are unknown but when triggered, it signals through the transmembrane adapter protein TYROBP DAP12 to activate phagocytosis of pathogens
- Ferried Into Brain, TREM2 Antibody Stirs Microglia | ALZFORUM
TREM2 antibody sports transferrin receptor binding domain to ease entry into brain It activated microglia and boosted brain glucose metabolism The antibody is in a first Phase 1 trial
- All Roads Lead to TREM2: Gearing Up to Target This Receptor
Since the discovery of rare, yet potent risk variants in the TREM2 gene 11 years ago, the microglial receptor has emerged as a pivot point in the pathogenesis of Alzheimer’s disease Findings presented at the International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to
- TREM2 - ALZFORUM
TREM2 encodes Triggering Receptor Expressed on Myeloid Cells 2, a transmembrane receptor that modulates microglial activity and survival TREM2 variants cause Nasu-Hakola disease (NHD), a rare autosomal recessive early-onset dementia, and may modify the risk of developing Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis
- TREM2 rs9357347 - ALZFORUM
A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression
- Antibodies Against Microglial Receptors TREM2 and CD33 Head to Trials
As neuroinflammation becomes ever more deeply implicated in Alzheimer’s disease, therapies targeting this process are starting to enter clinical trials At the 14th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 27–31 in Lisbon, Portugal, speakers presented
- TREM2 D87N - ALZFORUM
Ghani M, Sato C, Kakhki EG, Gibbs JR, Traynor B, St George-Hyslop P, Rogaeva E Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set
|